News & Updates

Mirtazapine, biperiden, and vitamin B6 are all beneficial in the treatment of antipsychotic-induced akathisia (AIA), with vitamin B6 having the best efficacy and tolerability profile, according to the results of a meta-analysis.

Among patients with mild-to-moderate COVID-19, viral rebound and symptom rebound occur frequently following a standard 5-day course of treatment with either VV116 or nirmatrelvir-ritonavir, as shown in a study from China.

New drug applications approved by US FDA as of 1-15 March 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

A lower delivered continuous kidney replacement therapy (CKRT) dose appears to be detrimental to critically ill patients with acute kidney injury (AKI), with a study showing that such an approach is associated with a higher 90-day mortality rate.

Among adults receiving benzodiazepine receptor agonist (BZRA), a limited number are considered continuous users and a small portion have moved to a higher-than-recommended dose, reports a study.

Twice-daily treatment with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) resulted in high viral suppression among people with HIV and tuberculosis (TB) who were on rifampicin-based therapy, according to the INSIGHT* trial presented at CROI 2024.

Patients who are suffering from hereditary angioedema (HAE) may find comfort by using drugs that have been recently shown to ease HAE attacks. Treatment with either garadacimab or berotralstat results in reduced attack rates, according to studies presented at AAAAI 2024.